Brief: Sernova Says Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial
27/10/2023 12:06
Oct 27 (Reuters) - Sernova Corp SVA.TO :
* SERNOVA ANNOUNCES POSITIVE ONGOING INTERIM PHASE 1/2
CLINICAL
DATA FOR THE CELL POUCH SYSTEM™ FOR TYPE 1 DIABETES TRIAL AT THE
2023 IPITA, IXA, AND CTRMS JOINT CONGRESS
Source text for Eikon: ID:nGNXblhYWl
Further company coverage: SVA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints